Background: Clopidogrel is an antiplatelet drug that is widely prescribed for cardiovascular disease. In 6 cardiac surgery, it is used in patients after coronary artery bypass grafting (CABG) to prevent 7 coagulation disorders. The irrational use of this drug can lead to bleeding and require surgical 8 exploration along with increased therapeutic cost. Therefore, it is essential to study the pattern of 9 clopidogrel use in hospitals. 10 Methods: This study was conducted for a 6-month period to evaluate clopidogrel adherence to American 11 Heart Association/American College of Cardiology (AHA / ACC) Guidelines in patients after coronary 12 artery bypass grafting (CABG) surgery. Patients' data were recorded in the pre-designed questionnaire, 13 which included demographic data, past medical history, drug history along with the indications of 14 clopidogrel use. Data analysis was performed by SPSS 16 software.
Introduction 30
Coronary artery bypass grafting (CABG) has become one of the most common cardiac procedures in 31 the United States and worldwide. 1,2 Antiplatelet therapy after CABG has been confirmed to increase the 32 patency of vein graft and to decrease postoperative related adverse events. 3 Clopidogrel is a thienopyridine derivative that inhibits platelet aggregation by antagonizing the P2Y12 37 platelet receptor. 5 Clopidogrel decreases ischemic events and mortality in patients with cardiovascular 38 diseases and its clinical efficacy has been established in some clinical trials. 6 39 AHA/ACC usually recommends clopidogrel for the following disorders: Unstable angina / non-ST- Collected data were analyzed using the SPSS version 16 (SPSS Inc, Chicago, IL, USA). For discrete 60 variables number and percentage and for continuous variables mean ± standard deviation was provided.
61
Spearman correlation test was used to evaluate correlation between the study variables. A p value of less 62 than 0.05 was considered as the statistically significant.
63

Results
64
In total, 120 patients were included in this study. Mean age of patients was 61.3 ± 8.9 years, and average 65 body mass index (BMI) was 27.5 ± 4.4kg/m 2 Male to female ratio was 3 times. Demographic and clinical 66 data are shown in Table 1 .
67
The most important risk factors in patients with cardiovascular disease in this study were male gender 68 (74.2%), hypertension (80%), and smoking (47.5%). Only 19.2% of patients had a positive family 69 history of cardiovascular disease. In addition to hypertension, some of the patients had diabetes mellitus 4 70 (39.2%), hyperlipidemia (37.5%), and MI (15%). As a result, the usage of cardiovascular drugs and anti-71 hyperlipidemic drugs had the highest frequency in patients' drug history. However, the most commonly 72 prescribed antiplatelet and anticoagulant drugs along with clopidogrel were aspirin (95.8%), heparin 73 (31.7%), warfarin (5%), and enoxaparin (2.5%). Indications of clopidogrel and antiplatelet/ 74 anticoagulant prescribed drugs have been included in Table 2 . Clopidogrel was prescribed in NSTEMI Table 3 . This study was conducted in order to evaluate and improve the rate of appropriate use of clopidogrel, as 82 a potent antiplatelet agent. The AHA and ACC have set guidelines for medical secondary prevention in 83 patients with cardiovascular disease, which contain detailed drug recommendations, diabetes and 84 hypertension management and lifestyle modifications such as sport and smoking cessation. In The 85 secondary prevention after coronary bypass, a Get with the Guidelines (GWTG) study, the adherence to 86 AHA and ACC guidelines was between 10% and 90%. Lack of awareness, information overload, and 87 incomplete documentation are some reasons for incomplete adherence to guidelines. The results of this 88 study showed that the compliance rate of aspirin (75 to 325 mg daily), and warfarin (with therapeutic 89 INR range 2 -3) were between 56% and 84 %. It was between 17% and 73%for beta-blockers (in post 90 MI and ischemic syndrome patients), and it was 24% for angiotensin-converting-enzyme inhibitors 91 (ACEI) (in post MI, congestive heart failure, and all vascular patients). 9 The study by Sørensen et al.
92
was about patients who underwent CABG following a recent MI. It assessed the benefits of postoperative 93 clopidogrel usage. Just 27% of 3545 patients received clopidogrel treatment after CABG, and they had 94 a lower risk of death or recurrent MI. 10 Another study by Robert F. et al. showed that the adherence to 95 secondary prevention guidelines in STEMI patients who underwent CABG was lesser than patients who 96 underwent PCI. Patients who received the more appropriate regimen of standard medical therapies were 97 PCI patients. Compliance rates have been improved between the 2 groups. In 2006, it reached 85.6% for 98 CABG group and 87.6% for PCI group. 11 our findings showed that compliance rate in our study were 99 70.8%. In the study performed by Farahzadi M the use of clopidegrol in primary management of patients 100 with NSTEMI and its adherence to ACC/AHA guidelines was investigated. Adherence to ACC/AHA 101 guideline for the management of NSTEMI in patients who presented to a tertiary health-care center was In this study only indication of clopidogrel was evaluated but no other indexes and aspects usage such 114 as loading as well as maintenance doses. Time duration that clopidogrel have been stopped before 115 CABG was not available in this study.
116
Other limitations include small sample size and partially short study period. More studies with large 117 sample size are needed to periodically evaluate the use of critical drugs in hospitals to improve treatment 118 outcome and save of therapeutic cost.
119
Conclusion
120
According to the results of this study, the current prescription of clopidogrel in patients after CABG 121 surgery is acceptable in our centre. 
